Literature DB >> 34110735

Chlamydial Pgp3 Seropositivity and Population-Attributable Fraction Among Women With Tubal Factor Infertility.

Gloria E Anyalechi1, Jaeyoung Hong1, Robert D Kirkcaldy1, Harold C Wiesenfeld2, Paddy Horner3, Gillian S Wills4, Myra O McClure4, Karen R Hammond5, Catherine L Haggerty6, Dmitry M Kissin7, Edward W Hook8, Michael P Steinkampf5, Kyle Bernstein1, William M Geisler8.   

Abstract

BACKGROUND: Chlamydial infection is associated with tubal factor infertility (TFI); however, assessment of prior chlamydial infection and TFI is imperfect. We previously evaluated a combination of serological assays for association with TFI. We now describe the chlamydial contribution to TFI using a newer Chlamydia trachomatis Pgp3-enhanced serological (Pgp3) assay.
METHODS: In our case-control study of women 19 to 42 years old with hysterosalpingogram-diagnosed TFI (cases) and non-TFI (controls) in 2 US infertility clinics, we assessed possible associations and effect modifiers between Pgp3 seropositivity and TFI using adjusted odds ratios with 95% confidence intervals (CIs) stratified by race. We then estimated the adjusted chlamydia population-attributable fraction with 95% CI of TFI.
RESULTS: All Black (n = 107) and 618 of 620 non-Black women had Pgp3 results. Pgp3 seropositivity was 25.9% (95% CI, 19.3%-33.8%) for non-Black cases, 15.2% (95% CI, 12.3%-18.7%) for non-Black controls, 66.0% (95% CI, 51.7%-77.8%) for Black cases, and 71.7% (95% CI, 59.2%-81.5%) for Black controls. Among 476 non-Black women without endometriosis (n = 476), Pgp3 was associated with TFI (adjusted odds ratio, 2.6 [95% CI, 1.5-4.4]), adjusting for clinic, age, and income; chlamydia TFI-adjusted population-attributable fraction was 19.8% (95% CI, 7.7%-32.2%) in these women. Pgp3 positivity was not associated with TFI among non-Black women with endometriosis or among Black women (regardless of endometriosis).
CONCLUSIONS: Among non-Black infertile women without endometriosis in these clinics, 20% of TFI was attributed to chlamydia. Better biomarkers are needed to estimate chlamydia TFI PAF, especially in Black women.
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34110735      PMCID: PMC9208281          DOI: 10.1097/OLQ.0000000000001434

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  26 in total

1.  Antibodies to Chlamydia trachomatis in serum and peritoneal fluid of women with endometriosis.

Authors:  Rafet Gazvani; Lucy Coyne; Tarja Anttila; Pekka Saikku; Jorma Paavonen; Alan Templeton
Journal:  Hum Fertil (Camb)       Date:  2011-03       Impact factor: 2.767

2.  Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study.

Authors:  Patrick J Horner; Gillian S Wills; Rosy Reynolds; Anne M Johnson; David A Muir; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure
Journal:  Sex Transm Infect       Date:  2013-02-21       Impact factor: 3.519

3.  Proportion of Tubal Factor Infertility due to Chlamydia: Finite Mixture Modeling of Serum Antibody Titers.

Authors:  A E Ades; M J Price; D Kounali; V A Akande; G S Wills; M O McClure; P Muir; P J Horner
Journal:  Am J Epidemiol       Date:  2017-01-06       Impact factor: 4.897

4.  Population-attributable fraction of tubal factor infertility associated with chlamydia.

Authors:  Rachel J Gorwitz; Harold C Wiesenfeld; Pai-Lien Chen; Karen R Hammond; Karen A Sereday; Catherine L Haggerty; Robert E Johnson; John R Papp; Dmitry M Kissin; Tara C Henning; Edward W Hook; Michael P Steinkampf; Lauri E Markowitz; William M Geisler
Journal:  Am J Obstet Gynecol       Date:  2017-05-19       Impact factor: 8.661

5.  Prevalence and persistence of Chlamydia trachomatis-specific antibodies after occasional and recurrent infections.

Authors:  Hanna Öhman; Tiina Rantsi; Päivi Joki-Korpela; Aila Tiitinen; Heljä-Marja Surcel
Journal:  Sex Transm Infect       Date:  2019-07-18       Impact factor: 3.519

6.  Predicting tubal factor infertility by using markers of humoral and cell-mediated immune response against Chlamydia trachomatis.

Authors:  Tiina Rantsi; Hanna Öhman; Mirja Puolakkainen; Aini Bloigu; Jorma Paavonen; Heljä-Marja Surcel; Aila Tiitinen; Päivi Joki-Korpela
Journal:  Am J Reprod Immunol       Date:  2018-10-03       Impact factor: 3.886

7.  Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection.

Authors:  Gillian S Wills; Patrick J Horner; Rosy Reynolds; Anne M Johnson; David A Muir; David W Brown; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure
Journal:  Clin Vaccine Immunol       Date:  2009-04-08

8.  Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes.

Authors:  Anne Z Steiner; Michael P Diamond; Richard S Legro; William D Schlaff; Kurt T Barnhart; Peter R Casson; Gregory M Christman; Ruben Alvero; Karl R Hansen; William M Geisler; Tracey Thomas; Nanette Santoro; Heping Zhang; Esther Eisenberg
Journal:  Fertil Steril       Date:  2015-09-25       Impact factor: 7.329

Review 9.  Evidence-based diagnosis and management of tubal factor infertility.

Authors:  Pinar H Kodaman; Aydin Arici; Emre Seli
Journal:  Curr Opin Obstet Gynecol       Date:  2004-06       Impact factor: 1.927

10.  Sera selected from national STI surveillance system shows Chlamydia trachomatis PgP3 antibody correlates with time since infection and number of previous infections.

Authors:  Paula B Blomquist; Stephanie J Mighelsen; Gillian Wills; Eleanor McClure; Anthony E Ades; Daphne Kounali; J Kevin Dunbar; Myra O McClure; Kate Soldan; Sarah C Woodhall; Patrick Horner
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.